Prostate Cancer Gene-Edited Cell Lines for Drug Discovery

Prostate carcinoma is the second most common cancer in men worldwide, with an estimated 1.4 million new cases and 375,000 deaths in 2020 (WHO GLOBOCAN). Incidence rates vary geographically, with the highest in Northern and Western Europe, North America, and Australia. Key risk factors include age (median age at diagnosis is 66), family history, and genetic predisposition (e.g., BRCA2 mutations). The 5-year relative survival rate for localized prostate cancer is nearly 100% (NCI SEER), but drops to 32% for distant-stage disease, highlighting the urgent need for better models of advanced and metastatic disease.

Prostate cancer is an ideal disease for mechanistic studies due to its well-characterized molecular subtypes (e.g., ERG fusion-positive, SPOP mutant, CHD1 loss), the availability of large public datasets (TCGA, cBioPortal, DepMap), and the presence of both androgen-dependent and castration-resistant forms. Open questions include the mechanisms of resistance to androgen receptor (AR) pathway inhibitors, the role of tumor microenvironment, and the identification of novel synthetic lethal interactions. Gene-edited cell models provide a powerful tool to address these questions with precision.

Prostate carcinogenesis involves several key pathways:

• • Androgen Receptor (AR) Signaling: AR activation drives proliferation and survival. Castration-resistant prostate cancer (CRPC) often involves AR amplification, mutations, or splice variants (e.g., AR-V7).
• • PI3K/AKT Pathway: Loss of PTEN (phosphatase and tensin homolog) is one of the most common alterations, leading to constitutive activation of PI3K/AKT signaling.
• • DNA Repair Pathways: Mutations in BRCA1, BRCA2, ATM, and other homologous recombination repair (HRR) genes are found in ~20% of metastatic cases, creating vulnerabilities to PARP inhibitors.
• • Cell Cycle Regulation: Loss of RB1 and TP53 is frequent in aggressive and neuroendocrine prostate cancer (NEPC).

Data from TCGA (Nature, 2015) and COSMIC (cancer.sanger.ac.uk).

Key signaling networks in prostate cancer include:

• • PI3K/AKT/mTOR: PTEN loss leads to AKT activation, promoting cell survival and growth. Key nodes: PI3K, AKT, mTOR, S6K.
• • MAPK/ERK: Often activated via RAS mutations (rare in primary, more common in metastatic) or upstream receptor tyrosine kinases (EGFR, HER2). Key nodes: KRAS, BRAF, MEK, ERK.
• • Wnt/beta-catenin: CTNNB1 mutations or R-spondin fusions activate beta-catenin, driving proliferation. Key nodes: beta-catenin, TCF/LEF, AXIN.
• • DNA Damage Response: ATM, ATR, CHK1, CHK2, and BRCA1/2 are critical for maintaining genome stability. Defects create synthetic lethality with PARP inhibitors.

Organoid models derived from patient tumors (e.g., from the Living Tumor Laboratory) better recapitulate the heterogeneity and microenvironment of prostate cancer, and can be gene-edited for functional studies.

• • Patient-Derived Xenografts (PDX): Implantation of human tumor tissue into immunodeficient mice (e.g., NSG). Preserves tumor heterogeneity and stroma. Examples: the LuCaP series, the PCa PDX panel from the Jackson Laboratory.
• • Genetically Engineered Mouse Models (GEMM): Conditional knockout of Pten and/or Trp53 in prostate epithelium (e.g., PB-Cre4; Ptenfl/fl; Trp53fl/fl). Develops invasive adenocarcinoma and NEPC.
• • Induced Models: Transgenic mice expressing SV40 large T antigen under the probasin promoter (TRAMP model). Develops progressive prostate cancer.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications, such as knockouts (e.g., TP53-/- in LNCaP), knock-ins (e.g., KRAS G12D in PC3), or reporter lines (e.g., AR-V7-GFP). These models eliminate confounding effects of genetic background, allowing direct causal inference. Commercially available, sequence-verified models are now available from several suppliers, accelerating research by providing ready-to-use tools for target validation, drug screening, and mechanistic studies. For example, isogenic pairs of PTEN wild-type and PTEN knockout cells can be used to study PI3K pathway dependence.

• • Knockout and knock-in lines are essential for validating candidate oncogenes and tumor suppressors. For example:
• • Knockout of AR in LNCaP cells confirms its role in androgen-dependent growth.
• • Knock-in of the SPOP F133V mutation in 22Rv1 cells demonstrates its effect on AR ubiquitination and stability.
• • Knockout of CHD1 in DU145 cells reveals its role in maintaining genomic stability.

Isogenic pairs (e.g., PTEN wild-type vs. knockout) are used in high-throughput screens to identify compounds that selectively kill cells with a specific genetic alteration. Resistance mechanisms can be modeled by generating cells with acquired mutations (e.g., AR F877L mutation conferring enzalutamide resistance). These models are critical for developing next-generation therapies.

• • CRISPR-based synthetic lethality screens in prostate cancer cell lines have identified vulnerabilities such as:
• • PARP1 inhibition in BRCA2-deficient cells.
• • ATR inhibition in ATM-deficient cells.
• • EZH2 inhibition in AR-negative, neuroendocrine-like cells.
• • These screens help identify biomarkers for patient stratification and combination therapy design.